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Abstract
Aim-To analyse the expression of multi-
drug resistance (MDR) related proteins at
different steps in colorectal carcinogen-
esis.
Methods-The presence of three MDR
related proteins (Pgp, MRP1, and LRP/
MVP) was studied by means of immuno-
histochemistry in normal, adenomatous,
and malignant colorectal epithelium. For-
maldehyde fixed, paraffin embedded tis-
sue sections of 17 samples of colorectal
tissue were used (normal mucosa, n= 4;
adjacent mucosa, n= 5; adenoma, n = 5;
carcinoma, n = 3).
Results-For all three proteins, expres-
sion was found in the surface epithelium
and the upper parts of the crypts in
normal colon. In the adenomas, staining
was seen along the complete length of the
crypts. In the carcinomas analysed, all
epithelium showed positive staining. Mu-
cosa adjacent to either carcinoma or
adenoma showed staining patterns mostly
resembling those of normal mucosa, but
sometimes some extension of staining was
seen along the crypt.
Conclusions-These proteins already
show increased expression in the adenoma
stage. In the absence of adequate mucin
production in adenomas, MDR related
proteins could be an important factor in
protecting the epithelium against further
environmentally induced genetic damage.
This could be one of the reasons why only
about 5% of colorectal adenomas will
actually progress to carcinomas.
( Clin Pathol 1999;52:450-454)
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Colorectal cancer arises from normal intestinal
epithelium through various genetic changes,
each contributing to oncogenesis. Dietary fac-
tors that determine the environment of the
intestinal epithelium are thought to play an
important role in this process. Agents entering
the mucosal cells from the stools can cause
genetic damage, thereby inducing progression
of the epithelium along the neoplastic
pathway.' In normal colonic mucosa defence
mechanisms are presumably active to eliminate
such toxic agents, or xenobiotics, from the cell.
Several mechanisms providing protection
against toxic agents (notably cytotoxic drugs)
have also been described in tumour cells.
Tumour cells often show broad cross resistance
between unrelated classes of cytotoxic drugs.
This phenomenon is known as multidrug
resistance (MDR).2 To date, at least two multi-
drug resistance mechanisms have been unrav-
elled, involving members of the ATP binding
cassette transporter superfamily, namely P
glycoprotein (Pgp) and the multidrug resist-
ance related protein (MRP1).
Pgp and MRP1 function as transmembrane
drug efflux pumps, decreasing intracellular
drug accumulation, thereby conferring resist-
ance to various natural product drugs.3 LRP/
MVP, which stands for "lung resistance related
protein/major vault protein," is another multi-
drug resistance related protein that was discov-
ered in a non-small-cell lung cancer cell line,
selected for doxorubicin resistance.8 The LRP/
MVP gene was cloned and identified as the
human major vault protein.9 Vaults are recently
described cellular organelles broadly distrib-
uted and highly conserved among diverse
eukaryotic cells.'0 Although different fromATP
binding cassette molecules, vaults have also
been implicated in transport of various sub-
strates, including cytotoxic drugs.."-'3 These
multidrug resistance related proteins (Pgp,
MRP1, and LRP/MVP) are broadly distrib-
uted in normal cells.""-6 High levels of Pgp have
been localised to the apical surfaces of small
and large intestinal epithelium.'7"'" MRP1 and
LRP/MVP expression has also been found in
the digestive tract.'4 16 Furthermore, frequent
Pgp, MRP1, and LRP/MVP expression was
found in cancers derived from mucosal tissues,
such as the colon.
Although the physiological function of the
multidrug resistance related proteins in the
various human tissues is unknown, the distri-
bution and combined expression in distinct
human cells implies a function in protection of
the cells against xenobiotics. Our aim in the
present study was to analyse the expression of
multidrug resistance related proteins at differ-
ent steps in colorectal carcinogenesis. To this
end we determined the presence of Pgp,
MRP1, and LRP/MVP by immunohistochem-
istry in normal colorectal epithelium, colorec-
tal adenomas, colorectal carcinomas, and
colorectal mucosa adjacent to adenomas or
carcinomas, using a panel of monoclonal anti-
bodies (MAb) that we have developed to the
multidrug resistance proteins Pgp, LRP/MVP,
and MRP 1.
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Methods
Formaldehyde fixed, paraffin embedded 4 gm
tissue sections of 17 samples of colorectal
tissue (normal mucosa from resection margins
of colectomy specimens further referred to as
normal mucosa, n = 4; normal mucosa adja-
cent to adenoma or carcinoma further referred
to as adjacent mucosa, n = 5; adenoma, n = 5;
carcinoma, n = 3) were obtained from the
tissue bank of the department of pathology of
the Free University Hospital. The monoclonal
antibodies JSB-120 and 4E32' raised against
Pgp, MRPrl and MRPm6 raised against
MRP1,22 and LRP-56 raised against
LRP/MVP8 were used. All antibodies are
murine except for the rat MAb MRPrl.
The formaldehyde fixed, paraffin embedded
tissue sections were deparaffinised in xylene,
rehydrated, and endogenous peroxidase activ-
ity was blocked by 0.3% (vol/vol) H,02 in
methanol for 30 minutes. For staining with
JSB- 1, 4E3, and MRPm6, paraffin sections
were pretreated with citrate buffer (0.01 M cit-
ric acid (pH 6.0) in distilled water) for 3 x five
minutes at 100°C in a microwave oven. Slides
were blocked with normal goat or rabbit serum
for 20 minutes and incubated with JSB-1 (1-4
jg/ml), 4E3 (5-10 ,ug/ml), MRPrl (10-20
gg/ml), MRPm6 (20-40 ,ug/ml), and LRP-56
(5-10 jig/ml) at 4°C overnight. All reagents
were diluted in phosphate buffered saline con-
taining 1% (wt/vol) bovine serum albumin
(PBS/BSA). A biotin-streptavidin immunoper-
oxidase (ABC) method was applied using
biotinylated goat anti-rat IgG (1:100, Jackson
Immmunoresearch Laboratories) or rabbit
anti-mouse IgG F(ab')2 (1:500, Dako) and
streptavidin conjugated to horseradish peroxi-
dase (1:500, Zymed). Bound peroxidase was
developed with 4 mg (wt/vol) 3,3'-
diaminobenzidine tetrahydrochloride (Sigma)
and 0.02% (vol/vol) H202 in 100 ml PBS; or 4
mg (wt/vol) 3-amino-9-ethylcarbazole and
0.02% (vol/vol) H202 in 0.1 M NaAc
(pH = 5.0). All slides were counterstained with
haematoxylin and mounted.
Positive controls for Pgp, MRP, 1 and
LRP/MVP staining included 4 gm sections
from formaldehyde fixed, paraffin embedded
tissue of histological normal adrenal gland and
lung. In addition, we used three doxorubicin
selected multidrug resistance tumour cell lines,
which were formaldehyde fixed and paraffin
embedded like the tissues23: SW-1573/2R160
(non-small-cell lung cancer; Pgp positive),
GLC4/ADR (small cell lung cancer; MRP1
positive), and SW-1 573/2R120 (LRP/MVP
positive).
Negative controls included both omission of
the first steps and substitution of the primary
antibodies by different non-reactive antibodies
of the same origin and isotype. Immunohisto-
chemical expression of the multidrug resist-
ance related proteins was evaluated and agreed
upon by three observers, on the basis of inten-
sity of staining, cellular distribution, and espe-
cially distribution in the colonic crypts.
Results
In the normal colorectal epithelium, the Pgp
antibody 4E3 showed strong cytoplasmic
membrane staining at the surface epithelium
and the very upper part of the crypts (fig 1A).
Occasionally, at this localisation some diffuse
cytoplasmic staining was also found. In the
adenomas, cytoplasmic membrane staining
was observed along the complete length of the
crypts (fig 1B). The cytoplasmic staining was
more pronounced than in the normal epithe-
lium. In the carcinomas an intense cytoplasmic
membrane staining was seen predominantly,
with diffuse cytoplasmic staining being even
more intense than in the adenomas (fig 1 C). It
was notable that mucosa adjacent to either car-
cinoma or adenoma showed staining patterns
mostly resembling those ofnormal mucosa, but
occasionally some extension of staining was
seen along the crypt, as in adenomas. A similar
pattern of staining for Pgp in the respective
colorectal epitheliums was found with JSB- 1.
In the normal epithelium, staining ofMRP1
was observed in the apical side of the
cytoplasm, just below the level stained with the
Pgp MAbs. The brush border and goblet cells
were completely negative, as reported before."6
Also for MRP1, surface epithelium and upper
parts of the crypts were clearly positive whereas
in the lower three quarters of the crypts only
some basal cytoplasmic staining could occa-
sionally be seen (fig ID).
In the adenomas, clear cytoplasmic staining
was seen for all cells throughout crypts, which
was finely granular (fig lE).
In the carcinomas, MRP1 staining was even
more intense than in the adenomas and showed
a more coarsely granular, apical cytoplasmic
staining (fig IF). Furthermore, the staining
pattern of adjacent mucosa mostly resembled
that of normal mucosa with occasionally some
extension of staining along the crypt. As
reported before, the staining intensity of
MRPm6 was somewhat weaker than that of
MRPrl, but similar staining patterns were
observed. 16
As detected by LRP-56, the distribution of
LRP/MVP in the colorectal mucosa was, like
MRP1, predominantly granular in the outer
zone of the cytoplasm, just below the Pgp
staining. Strong cytoplasmic staining was seen
in the surface epithelium and upper parts ofthe
crypts in normal epithelium (fig 1 G), com-
pared with diffuse cytoplasmic staining of the
whole crypt in adenomas (fig 1H). This stain-
ing pattern was also observed in the cytoplasm
of carcinomas (fig 1 1). The distribution of
staining in adjacent mucosa was similar to that
found for MRP1.
In colorectal adenomas an abrupt change
from substantially normal epithelium to adeno-
matous epithelium could occasionally be found
within a single crypt.24 This allows one to
observe within one crypt the contrasting levels of
the multidrug resistance related proteins be-
tween neoplastic and non-neoplastic epithelium.
Low levels of Pgp, MRP1, and LRP/MVP were
observed in the non-neoplastic epithelium. Pre-
cisely where stratification of nuclei indicates the
start of neoplastic change, a definite increase of
451
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multidrug resistance related protein levels was
seen (fig 1J-L).
Discussion
There is much evidence to support the view
that mutagenic agents in the environment of
the colorectal epithelium-that is, the luminal
contents of the gut-play a major role in the
aetiology of colorectal cancer. Bile acids, muta-
gens formed by frying of fat and meat, and
bacteria produced mutagens have all been
associated with colorectal carcinogenesis.25.27 It
is most likely that in the normal colonic
mucosa protection mechanisms are active to
eliminate these toxic agents, or xenobiotics,
from the cell into the lumen. Since multidrug
resistance related proteins have been shown to
be physiologically present in the normal color-
ectal epithelium they are good candidates for
involvement in this detoxification process. Pgp
is prominently expressed in the apical cytoplas-
mic membranes of organs with excretory
functions."7 18 Recently, in colon cell lines the
efflux of benzo [a]pyrene, a dietary carcinogen,
was shown to be dependent on the activity of
Pgp, indicating a possible role of Pgp in the
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Figure 1 (A) Pgp staining in paraffin sections ofnormal colorectal epithelium with the 4E3 monoclonal antibody shows
strong membrane staining at the surface epithelium and the very upper part of the crypts, with occasional slight cytoplasmic
staining. (B) Adenomas show membrane staining along the complete length of the crypts with stronger cytoplasmic staining
than in the normal epithelium. (C) Carcinomas show intense membrane staining, and the diffuse cytoplasmic staining was
even more intense than in the adenomas. (D) MRP1 ofnormal colorectal epithelium with the MRPrl monoclonal antibody
shows apical cytoplasmic staining, with the brush border and goblet cells completely negative. The surface epithelium and
upper parts of the crypts are clearly positive whereas in the lower three quarters of the crypts only some basal cytoplasmic
staining can occasionally be seen. (E) In the adenomas, a clear,fine granular cytoplasmic staining is seen along the whole
length of the crypts. (F) In the carcinomas, staining with MRPrl was even more pronounced than in adenomas and
showed a coarsely granular cytoplasmic pattern with more intense staining near the plasma membrane. (G) LRPIMVP
staining ofnormal colorectal epithelium with the LRP-56 monoclonal antibody shows strong cytoplasmic signals in the
surface epithelium and upper parts of the crypts. (H) Diffuse cytoplasmic staining of the whole crypt is seen in adenomas.(I) Strong cytoplasmic staining occurs for the carcinomas. ((A), (D), (G): Surface of the normal epithelium is at the top of
the figure; (B), (E), (H): Surface of the adenomas is at the left of thefigure. In adenomas the crypts are longer and moreirregular; (C), (F), (I): Only central parts of the carcinomas are shown, no surface visible. Panels (A)-(I), x20 objective).() High power view of the 4E3 stainingfor Pgp in an adenomatous crypt with an abrupt changefrom substantially
normal epithelium to neoplastic epithelium. In the non-neoplastic epithelium (right) no staining of the goblet cells andintense cytoplasmis membrane staining of the absorptive cells is seen. In the adenomatous epithelium (left) diffuse
cytoplasmic staining is seen. The membrane staining of4E3 also seen in adenomas is not very clear in this area. (K) For
MRP1 stained with MRPr1, predominantly basal staining is seen in the normal epithelium (right), with slighdy stained
absorptive cells in between the goblet cells. Precisely where stratification of nuclei indicates the start of neoplastic change(left), a definite increase in MRP1 expression is seen. (Ll) The same holds true for LRPIMVP detected with LRP-56.(Panels (J)-(L), x63 objective.)
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protection of colorectal epithelium against car-
cinogenic agents.28 In both a model system of
mature rat enterocytes and in vivo in humans,
the activity of mdrl -the gene coding for
Pgp-was inducible by several compounds
including commonly used oral antibiotics.29
MRP 1 and LRP/MVP staining is different
from the predominantly membrane staining
observed for Pgp. The granular cytoplasmic
staining pattern of MRP1 and LRP/MVP in
colonic epithelium suggests a role for these
proteins in the transport of compounds into
intracellular compartments. An additional
complication is the possibility that transporters
are differentially rerouted in the cell.30 Evers et
al found transport of a glutathione-S-conjugate
and daunorubicin in a human MRP 1 trans-
fected kidney cell line. In these epithelial cells
MRP1 is localised mainly to the basolateral
plasma membrane, unlike Pgp which is local-
ised more apically.3' The physiological role of
MRP1 and its recently identified homologues
cMOAT and MRP3-6 is still unknown.32 In
vivo studies showed that MRP1 can act as a
pump for drugs conjugated to glutathione
(GSH), or glucuronides.33-35 Alternatively, drug
efflux by MRP1 could occur by a cotransport
mechanism involving reduced GSH and possi-
bly other anions.36
The physiological function of LRP/MVP
also remains to be resolved. Although different
from ATP binding cassette molecules like Pgp
and MRP1, the major vault protein LRP/MVP
has also been implicated in transmembrane
transport of various substrates." 12 The obser-
vation that vault synthesis is linked directly to
multidrug resistance supports a direct role for
vaults in drug resistance.'3 Direct proof that
vaults are actually able to transport cytostatic
drugs, however, is still lacking. Clinical interest
in LRP/MVP relates to recent studies in which
LRP/MVP expression was predictive of poor
response to chemotherapy. In normal human
tissues LRP/MVP expression showed distinct
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Figure 2 Increased expression of the multidrug resistance related proteins Pgp, MRP1, and
LRPIMVP in adenomas could be secondary to mucin depletion. In normal colorectal
mucosa (left), the continuous production andflow of mucin by goblet cells protects especially
the deeper parts of the crypts from carcinogenic agents from the stools. Only at the surface
and in the upper parts of the crypts are xenobiotic pumps active. In the adenomatous
(neoplastic) crypts (right), the lack of mucin facilitates a higher concentration of xenobiotics
in the deeper parts of the crypts and as a result the expression of xenobiotic pumps is
induced to levels normally only seen at the surface epithelium.
patterns suggesting a role in detoxification
processes, similar to Pgp and MRP 1.14
It could be hypothesised that a disturbance
of the balance between attack and defence
mechanisms-for example, by impaired func-
tioning of xenobiotics pumps-could be an ini-
tiating step in the pathogenesis of colorectal
cancer. One then would expect a decreased
expression of these proteins in the precursor
lesion of colorectal cancer, the adenoma. How-
ever, this is clearly not what we found for Pgp,
MRP1, and LRP/MVP. On the contrary,
adenomas already showed increased expression
of these proteins, as detected by the mono-
clonal antibodies in our present study. This
increased expression of Pgp, MRP1, and LRP/
MVP occurs early during oncogenesis and
appeared to be directly related to the change
from non-neoplastic to neoplastic epithelium
(fig 1, J-L).
Increased expression of these multidrug
resistance related proteins could be explained
in several ways. First, genetic changes underly-
ing the neoplastic phenotype could also cause
the increased expression of xenobiotic pumps.
Two closely related genes, MDR 1 and MDR
3, which encode highly homologous P glyco-
proteins in humans, are both located at the
long arm of chromosome 7. Indeed, extra
copies of chromosome 7 have often been
observed in colorectal adenomas.37 However,
gain of the short arm of chromosome 16, where
the genes for MRP1 and LRP/MVP are
located, was reported in only two of 23
colorectal tumours (nine adenomas and 14
carcinomas).9 38 39 For most colorectal tumours
it is therefore unlikely that the increased
expression of MRP1 and LRP/MVP can be
explained in this way.
Second, increased expression of Pgp, MRP1,
and LRP/MVP could be a non-specific feature
ofimpaired differentiation, which is a feature of
neoplastic epithelium. This, however, does not
fit very well with the observation that Pgp
expression was less in poorly differentiated
colorectal cancers than in well differentiated
tumours. 9 MRP 1 expression has also been
negatively correlated with differentiation in
lung cancers.40
A more plausible explanation is that the
increased expression of xenobiotic pumps
occurs secondary to the failure of some other
defence mechanism. One of the main protec-
tive mechanisms present in the colorectal
epithelium is the continuous production and
flow of mucin by goblet cells. One of the
features of neoplastic (or dysplastic) colorectal
epithelium is lack of mucin.4' The lack of
mucin may facilitate a higher concentration of
xenobiotics in the deeper parts of the crypts
and as a result the expression of multidrug
resistance related proteins may be induced to
levels normally only seen at the surface epithe-
lium (fig 2).
Colorectal cancer is regarded to be intrinsi-
cally resistant to chemotherapy that is, resist-
ant to chemotherapy at the time of diagnosis, a
feature shared with other cancers associated
with an increased exposure to carcinogens like
small cell lung cancer. This resistant phenotype
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fits with the findings of our present study,
showing increased expression of Pgp, MRP1,
and LRP/MVP in adenomas which are precur-
sors of colorectal cancers. This observation
may also have implications for chemopreven-
tion, which aims at preventing the development
of colorectal cancers by dietary modifications
or supplementation with agents believed to
reduce the risk of such cancers.42 Possibly cer-
tain chemopreventive agents may not reach
adequate concentrations in the epithelium of
adenomas because they are rapidly cleared
from the cytoplasm by xenobiotic pumps. Thus
certain chemopreventive agents might be less
effective once an adenoma has occurred.
Multidrug resistance related proteins are
likely to be players in the field of interaction
between environmental agents and cell biologi-
cal defence mechanisms in the colonic mucosa.
The results of the present study indicate that
some of these proteins already show increased
expression in adenomas. In the absence of
adequate mucin production in adenomas,
multidrug resistance related proteins could be
an important factor in protecting the epithe-
lium against further environmentally induced
genetic damage (fig 2). This could be one of
the reasons why only about 5% of colorectal
adenomas actually progress to carcinomas.
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